Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Erbitux First-Line Studies Face Enrollment Challenges From Avastin

Executive Summary

ImClone is moving Erbitux development forward with an eye on enrollment

You may also be interested in...



Amgen 2004 R&D Goals Focus On Oncology, Osteoporosis Products

Amgen's 2004 R&D targets include a BLA filing for palifermin for reduction of oral mucositis associated with radiation and chemotherapy in patients with hematologic malignancies

Amgen 2004 R&D Goals Focus On Oncology, Osteoporosis Products

Amgen's 2004 R&D targets include a BLA filing for palifermin for reduction of oral mucositis associated with radiation and chemotherapy in patients with hematologic malignancies

Erbitux Priced For Late Stage Use, ImClone Says; McKesson Is Sole Distributor

The pricing strategy for the oncologic Erbitux reflects the expectation that the biologic will be used primarily in late stage disease, ImClone CEO Daniel Lynch told analysts during a March 15 conference call

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel